Oppenheimer Asset Management Inc. Neurocrine Biosciences Inc Transaction History
Oppenheimer Asset Management Inc.
- $7.78 Billion
- Q1 2025
A detailed history of Oppenheimer Asset Management Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 13,993 shares of NBIX stock, worth $1.85 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
13,993
Previous 13,944
0.35%
Holding current value
$1.85 Million
Previous $1.9 Million
18.71%
% of portfolio
0.02%
Previous 0.02%
Shares
26 transactions
Others Institutions Holding NBIX
# of Institutions
650Shares Held
96.9MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.88 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.31 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$731 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$642 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$353 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...